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Abstract
Research into advanced therapeutic materials is of growing importance worldwide, particulary
in the disease areas of infection, neurodegeneration and oncology. Advances have been made
in treating all these diverse pathologies but there still remain many areas of challenge. Amongst
the most difficult are those involving highly potent and/or cytotoxic agents which present the
inherent problem of adverse off-target effects. Of key importance is to widen the therapeutic
window for such agents by reducing access to non-diseased cells and enhancing release at
targeted sites. Spatiotemporal controlled release can be achieved by exploiting physical,
chemical or biological stimuli present at the specific diseased area. A crucial strategy involves
drug-carrier linkages able to respond to physiological or biochemical stimuli present in the
disease region, and there is now significant literature on (polymeric) pro-drugs based on the
drug+carrier+cleavable linker philosophy, predominantly for cancer applications. We have
therefore focused this mini-review mainly on single/multi-stimuli-responsive pro-drugs for
cancer therapies, covering some of the leading examples of pro-drug chemistries used to endow
polymers with controlled and site-specific drug delivery properties. Additionally, we have
emphasized the possibilities for exploiting similar approaches to disease-associated stimuli
2present in infections, both bacterial and viral, in inflammatory and immune diseases, and in
degenerative disorders.
1. Introduction
The requirement to deliver bio-active agents selectively to target sites in the body, for diagnosis
and therapy, is a major focus for research in the physical and biomedical sciences.[1] While there
have been important advances in recent years,[2] with a number of academic papers describing
successful targeted therapies in small-to- medium scale trials,[3] there remain significant unmet
needs in drug delivery and complex scientific and clinical challenges to overcome.[4]
There are multiple disease areas in which targeted drug delivery could be transformative, but
the most extensive research has been carried out in cancer drug delivery.[5] This is because
many, though by no means all, anti-cancer agents are designed to be highly cytotoxic, and thus
have the inherent problem of adverse off-target effects. Accordingly, the focus for many
researchers in the field has been to widen the therapeutic window for these agents, by reducing
their access to non-diseased cells and enhancing their release at the targeted sites. The
mechanisms by which this strategy can be accomplished include the use of physical, chemical
or biological stimuli at the points where drug delivery systems spatially encounter the diseased
regions.[6] Of particular importance have been methods to encode chemistries in the drug-carrier
linkage which are activated by physiological or biochemical cues present in the disease region.
This pro-drug approach has been very widely trialed in more conventional therapeutics, and
indeed many drugs that are taken routinely by patients, such as aspirin, are in fact pro-drugs.
The anti-cancer drug tamoxifen can also be considered as a pro-drug, since a number of its
metabolites such as 4-hydroxytamoxifen are more potent in certain patients than the parent
drug. There is now a wide-spread literature on pro-drugs and it is not surprising that some of
3the pioneering examples of polymer therapeutics for cancer were based on a
drug+carrier+cleavable linker philosophy.[7]
We have therefore focused this mini-review primarily on stimuli-responsive pro-drugs for
cancer therapies, but emphasize that similar approaches can exploit disease-associated stimuli
present in infections, both bacterial and viral, in inflammatory and immune disorders, and in
degenerative disorders.[8] The specific stimuli include altered redox states, secretion of
cytokines and other signaling molecules, so in principle can be exploited by many of the
mechanisms already used to activate anti-cancer systems. We thus outline below the main
classes of activating chemistries used in oncological drug delivery while alerting the reader to
the many possibilities for other therapeutic areas which may be addressed in similar ways.
Importance of responsive linker pro-drug chemistry for drug delivery
The development of nanoparticles which can be injected into a patient and which circulate for
prolonged time periods to effect therapy is a demonstrable achievement of drug delivery
research.[9] Further optimization of active and passive targeting mechanisms have allowed for
the delivery of nanoparticles specifically to disease sites of interest. With many targets and
targeting ligands available to enhance selective tumor accumulation of nanoparticles, the
development pathway for anti-cancer drug carriers has often focused on specific ligand
functionalization to improve the delivery process. However, in order to maximize delivery of
therapeutics to sites of interest while minimizing adverse side effects due to non-specific
toxicity, it is important not just to take the carrier to the target site, but to ensure that the
therapeutic agent is stable within the delivery system and only released when the disease region
is reached. This outcome is harder to achieve for drugs physically entrapped within a carrier,
hence the drive for pro-drug mechanisms of in situ drug release.
2. Methods of stimuli-responsive drug delivery
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to the poor water solubility of many commonly used drugs, as well as the short biological half-
lives typical for small molecules in vivo. This results in a low bioavailability of the drug in vivo
and high doses that need to be administered to counteract this. Additionally, it is well known
that systemic delivery of small molecule drugs can result in non-specific toxicity in other areas
of the body, potentially resulting in severe side-effects, which are exacerbated by the high doses
needed for a therapeutic effect. Physical encapsulation of therapeutics within the core of stealth
nanoparticles such as liposomes or vesicles was an initial approach to overcome these
drawbacks. This method however can display variable loading efficiencies of the therapeutic,
where a dependence on particle material, drug solubility, drug-particle interactions, functional
groups of both the drug and the particle material and loading conditions heavily dictate the
successful inclusion of the therapeutic within the nanocarrier.[10] Additionally, physically
entrapped drugs typically display less controlled release rates, with burst release commonly
seen.[11]
An alternative approach is to attach instead the drug through a covalent linkage, forming a
prodrug, which contributes numerous advantages to a drug delivery system when used in
conjunction with both passive and active targeting. While covalent attachment requires more
sophisticated synthesis requirements, the resultant system will typically be more stable to
unwanted burst release of the drug, can facilitate a higher loading efficiency, and provides
additional control over both the rate of the release and the site of drug release in vivo.[12]
Pathological sites such as tumor tissues and inflamed wounds when compared to the healthy
tissues exhibit abnormalities such a low pH, hypoxia, high temperature, over-expressed proteins
and enzymes and elevated levels of reactive small molecules such as metabolites and Reactive
Oxygen Species (ROS). Such characteristic properties of disease sites have therefore been used
to design functional prodrug carriers to obtain site specific delivery and controlled release of
therapeutic payloads (Table 1). These programmed prodrug carriers can thus undergo specific
5physio-chemical transformations such as molecular structural rearrangements, disassembly,
inversion or disassociation into sub units triggered by these bio-relevant cues/abnormalities at
targeted sites for site specific release of the drug load.[13]
Table 1. Examples of responsive linkers adopted for stimuli-driven prodrug controlled release
Stimuli Responsive linkers References
pH
O
Si
O
R
R
silyl ether
16-21, 65, 67
enzyme 23-29, 64-66
oxidative
O B
O
boronate ester
31-38, 58, 59,
62, 69
redox 41-47, 62, 64,
66-69
self-
immolative
50-57, 68
Typical endogenous stimuli that are exploited for this purpose are pH, concentrations of
enzymes, redox potential and oxidative conditions, as well as additional exogenous stimuli such
as light, infra-red light (IR), ultrasound and magnetic field, which will not be discussed
here.[6b, 14] Degradation in these specific environments can be controlled through the specific
linkage used for attachment of the drug to the nanoparticle carrier, and therefore this component
6is of particular importance. This review summarizes the current methods of stimuli-responsive
drug delivery achieved through covalent prodrugs, as well as offering insight and a reference
point for further development of these systems in the future.
Endogenous stimuli-responsive drug delivery
pH responsive systems
Covalent linkages that are acid-labile can be employed to exploit both the acidic extracellular
environment of tumors (~pH 6.5) due to the irregular angiogenesis in fast-growing tumors, as
well as the acidic environment of endosomal and lysosomal vesicles within a cell (~pH 5).[15]
Nanoparticles internalized through receptor-mediated endocytosis will enter the cell in vesicles,
which acidify causing a local environment of pH ~5-6, as well as fusion with lysosomes (pH
~4-5). This can be exploited through degradable covalent drug conjugations, such as acid-
sensitive acetal, ester, Schiff-base, silyl ether and hydrazone bonds.
Acetal-based prodrug delivery systems have several advantages, namely fast degradation in
acidic conditions and an absence of acidic degradation products. Gu and coworkers used this
strategy to prepare acetal-linked paclitaxel (PTX) prodrug nanoparticles for delivery to various
cancer cell lines.[16] They attached PTX onto block copolymers of poly(ethylene glycol)-b-
poly(acrylic acid) (PEG-PAA) via an acid-labile acetal bond to the PAA block, and the prodrugs
could self-assemble into micelles. They showed pH-dependent drug release, with minimal
release of the drug in physiological conditions and accelerated release under acidic pH
conditions. The micelles could impart toxicity in vitro in KB and HeLa cancer cells, as well as
paclitaxel-resistant A549 cells, which was attributed to local release of the drug, as well as
hydrolysis of the acetal linkage resulting in release of paclitaxel in its native state, ensuring
maximum efficacy of the drug.
Parrott et al.[17] described a pH-responsive drug delivery system based on acid-labile silyl ether
functionalized prodrugs of gemcitabine (GEM). The prodrug could be polymerized into a
7nanoparticle for additional protection of the drug during circulation, and they varied the side
groups of the silyl ether in order to investigate the effect on rate of drug release. They were able
to show that by increasing the steric bulk of the substituents on the silyl group, they could tune
the release of the drug in an acidic environment to be in hours, days, or months, and that this
effect was enhanced when the particles were in an acidic environment, such as that within
endosomes. Finally, they showed that the nanoparticles could impart toxicity on LNCaP tumor
cells through hydrolysis of the silyl ether, resulting in local delivery of gemcitabine. This
approach was also explored by Yan and coworkers, who utilized silyl ether prodrugs of the
chemotherapeutic camptothecin to achieve controlled release from mesoporous silica
nanoparticles (MSN).[18] They synthesized both trimethyl silyl ether and triethyl silyl ether
derivatives of the drug, which were then covalently bonded to the surface of the nanoparticles.
Their conjugates showed minimal drug release in physiological pH 7.4, but in an acidic
environment showed accelerated hydrolysis and release of the drugs, with the methyl derivative
demonstrating a faster release profile than the ethyl derivative due to steric bulk. Both
conjugates were able to impart toxicity to cells at a similar levels to that of the free drug.
Figure 1. Illustration of an acid-responsive silyl ether prodrug being released from an MSN-SH nanocarrier (MSN-
mesoporous silica, SH-thiol, Me-methyl, Et-ethyl, CPT-Camptothecin). Reprinted with permission from ref 18.
Copyright 2017 Elsevier.
Zhou et al.[19] developed drug delivery particles from the self-assembly of amphiphilic N-(2-
Hydroxypropyl) methacrylamide (HPMA) copolymers, featuring prodrugs of doxorubicin and
8β-sitosterol attached to the polymer backbone through acid-labile hydrazone linkages. 
Following self-assembly to form micelles, the polymers were further crosslinked via hydrazone
bonds for physiological stability. The micelles remained stable at pH 7.4 with minimal drug
release observed, however at pH 5.0 the micelles were able to release approximately 80% of
the drugs after 8 hours. While in vitro IC50 values in Hep G2 and A549 cell lines were similar
for both the crosslinked and non-crosslinked micelles, in an in vivo mouse xenograft
hepatocarcinoma model, the crosslinked micelles showed higher tumor accumulation and an
improved anti-tumor effect over the non-crosslinked micelles.
Similarly, Thurecht and coworkers synthesized acid-labile prodrugs of doxorubicin (DOX) by
attaching the drug to PEGMA [poly(ethylene glycol methacrylate]-based hyperbranched
polymers through hydrazone bonds.[20] The polymers were stable at pH 7.4 with less than 5 %
drug release, but showed controlled release of the drug in acidic pH conditions. The polymers
were able to be localized within tumor cells in vitro, and demonstrated comparable cytotoxicity
to free drug. Hydrolysis of the hydrazone linkage in vitro was confirmed through confocal
imaging, where the drug could be seen to overlay with polymer signal initially in endosomes,
followed by transport into the nucleus alone, as observed through the innate fluorescence of
doxorubicin. Finally, the conjugate was able to induce a therapeutic effect on prostate cancer
xenograft tumors in vivo, with a significant reduction in tumor volume compared to free drug
and controls.
Jia et al.[21] reported an anticancer acid-labile prodrug of doxorubicin, where they utilised pH-
sensitive Schiff-base linkages to achieve stimuli-responsive drug delivery. The prodrug
comprised unimolecular micelles of star-like amphiphilic copolymers, synthesized from
benzoaldehyde and hydrophilic poly(ethylene glycol methyl ether methacrylate), with the
doxorubicin attached to the copolymer benzoaldehyde groups via Schiff-base. The micelles
showed stability in physiological conditions, with an increase in drug release observed over
time in a pH 5.0 environment, as well as improved control over release kinetics as compared to
9physically encapsulated micelles of DOX. In vitro experiments confirmed that the unimolecular
micelles could be internalised by human cervical cancer HeLa cells and impart toxicity
following hydrolysis of the Schiff-base.
Enzyme-responsive systems
Enzyme dysregulation is observed in many disease-associated microenvironments, and thus has
been exploited as a powerful tool in the nanomedicine field for the development of enzyme-
responsive nanomaterials, which are able to specifically target the affected site and thereby
regulate drug release. Several more broad overviews covering the developments in enzyme-
responsive liposomes and polymeric linkers/nanoparticles, as well as their adoption into the
controlled drug-delivery field are discussed from different perspectives and degree of detail in
these recent suggested reviews.[22]
A preliminary example involving physical encapsulation of drugs is described by Aluri et al.,[23]
who developed a novel class of enzyme-responsive comb-like poly(ester-urethane)s based on
naturally occurring L-Tyrosine amino acids. The amine and carboxyl moieties were converted
into dual function ester-urethane functionalities, and then subjected to solvent-free melt
polycondensation, adopting PEG chains as spacer units. The amphiphilicity of the materials
was optimized by tuning the length of the hydrophilic PEG chains and the nature of the alkyl
side chains anchored to the L-Tyrosine phenolic residue. Stable nanoparticles of 200 nm were
formed through self-assembly of the materials in an aqueous environment, and clinically
relevant drugs such as DOX and Camptothecin were successfully encapsulated, with the drug-
loaded nanoparticles demonstrating good stability in simulated extracellular conditions.
However, in an environment of esterase enzymes, the nanoparticles underwent rapid
biodegradation with subsequent cargo-release, exclusively in the intracellular conditions. The
drug-loaded nanoparticles demonstrated improved cytotoxicity and selectivity, as well as higher
cellular internalization compared to the free drugs.
10
Figure 2. Designing of new classes of L-tyrosine based amiphiphilic poly(ester-urethane)s and employ their enzyme-
responsive self-assembled nanoparticles as multiple anticancer drugs in cancer cells. Reprinted with permission from
ref 23. Copyright 2017 American Chemical Society.
Gianneschi’s group developed a library of novel polymers used as a nanoparticle platform with
high targeting recognition of matrix metalloproteinases (MMPs), which are over-expressed in
an array of cancer types and present as catalytic, extracellular or membrane-bound tumor
markers.[24] In an elegant attempt to apply this smart, enzyme-sensitive nanoparticle platform
as a chemotherapeutic delivery system, two monomers were designed and synthesized as
norbornene derivatives to be polymerized via ring opening metathesis polymerizations
(ROMP).[25] A hydrophobic monomer was achieved through direct biodegradable ester-linkage
of the norbornene scaffolds with the potent anticancer drug paclitaxel (PTX-up to 63 % drug
loading in the final micelles), while a hydrophilic monomer was decorated with a specific
peptide sequence to endow the formed micelles with a motif for MMP recognition. Upon
exposure to the enzymes, the micelles underwent a significant morphology change from well-
defined 20 nm particles to microscale structures. The safety and efficacy of the materials were
assessed through a variety of in vivo proof-of-concept studies. The nanoparticles demonstrated
enhanced selectivity for the tumor site, and minimal off-target toxicity was observed for the
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drug-loaded nanoparticles, as well as no observed adverse effects from the non-responsive
nanoparticles. The resultant nano to micro size transition achieved in the tumor environment
allowed for enhanced nanoparticle accumulation and controlled drug release. By varying the
nature of the peptide sequence and the nature of the hydrophobic core, the same group has
since developed a series of innovative enzyme-responsive polynorbornene platforms for the
efficient targeting of ischemic tissues,[26] as well as a unique non-invasive delivery of a material
scaffold to acutely infarcted myocardium.[27]
In addition to anticancer therapies, there is also a growing application of enzyme-responsive
materials for bacterial-strain targeted delivery of antimicrobial agents.[28] In this regard, Li et
al.[29] developed polymeric vesicles that undergo self-immolative degradation in response to
enzymes such as penicillin G amidase and β-lactamase. The degradative action of these 
enzymatic systems, which are closely related to drug-resistant bacterial strains, led to the
controlled and sustained release of the payload antibiotics.
ROS-responsive systems
It has been shown that, compared with their normal counterparts, many types of tumor cells
consistently produce a high level of ROS, due to their accelerated aerobic metabolism, such as
superoxides (O2–), hydroxyl radicals (·OH), hypochlorite ions (OCl–), hydrogen peroxides
(H2O2), and singlet oxygen species (1O2).[30] Therefore, these increased levels of ROS can be
exploited as endogenous stimuli for specific drug release through the use of oxidative-sensitive
linkages. There are many types of ROS-responsive materials explored in drug delivery
applications, including those containing characteristic groups such as thioether,
selenium/tellurium, thioketal, boronic ester, sulfide and ferrocene groups.
Hagen et al.[31] described an aminoferrocene-based polymer prodrug, targeted towards specific
tumoricidal behaviour in the enhanced ROS environment of cancer cells. The ROS-responsive
ferrocene groups were activated from their non-toxic dormant state by the oxidative conditions,
producing a toxic quinone methide species, as well as an efficient catalyst for further ROS
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production. Their organometallic complexes exhibited enhanced anticancer activity in cellular
assays, and targeted cancer cells selectively over normal cells. The activation reaction
proceeded autocatalytically, which led to the generation of large quantities of ROS in cancer
cells causing selective toxicity towards human promyelocytic leukemia and human
glioblastoma-astrocytoma, but were non-toxic towards representative nonmalignant cells.
Aryl boronic acids and their esters are well-known to be cleaved by H2O2.[32] Based on this, as
well as the nontoxicity of boronic acids, esters, and the end product boric acid, Kuang et al.[33]
designed and synthesized boronate prodrugs of nitrogen mustards and investigated their
inducible reactivities in cancer cells. In the absence of H2O2, the prodrug remained nontoxic to
cells, indicating that the prodrug complex masked the toxicity of the nitrogen mustard
mechlorethamine, however in the presence of H2O2 the boronic ester could selectively react
with H2O2 to form a boronate intermediate that rapidly hydrolyzed causing the drug to be
released. The active drug could impart toxicity to the cells through its mechanism of causing
DNA interstrand cross-links, resulting in cell death by preventing cell replication and
transcription. In a further study,[34] they investigated more efficient boronic ester prodrugs based
on quinone methide, that could additionally be coupled with multiple potent effectors to
maximise the ROS-inducible cytotoxicity of prodrugs. The anticancer prodrugs were activated
with different functional leaving groups, and thus under tumor-specific conditions (high level
of ROS), the arylboronic esters were readily cleaved by the H2O2 to release 2,5-
bis(trimethylammonium)-benzyl-1,4-diol, which generated biquinone methide in situ, as well
as two additional effectors that promoted increased quinone methide production.
Boronate ester-based ROS sensitivity was also exploited by Daniel et al.,[35] where they
designed a block copolymer prodrug system that could self-assemble in aqueous conditions to
form particles. The prodrug consisted of an inhibitor for matrix metalloproteinases (MMPs),
which are commonly found in areas of increased ROS concentration, tethered to the polymer
backbone through an aryl boronic ester moiety. The stimuli-responsive linker was stable under
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normal physiological conditions, however could undergo nucleophilic attack by H2O2, resulting
in the expulsion of a phenolate intermediate, which could spontaneously release the MMP
inhibitor. In a similar approach, Zhang et al.[36] synthesized a polymer-drug conjugate of
camptothecin containing an ROS trigger-responsive domain. In their work, camptothecin was
conjugated to a polymer carrier through carbamate linkages attached to a central ROS-
responsive boronic ester group. Exposure to increased levels of H2O2 caused the boronic ester
group to be cleaved, resulting in a cascade self-immolative degradation of the polymer prodrug
resulting in drug release. The conjugates demonstrated significantly increased cellular apoptosis
of cancer cells both in vitro and in vivo when exposed to elevated levels of ROS, compared to
the same polymer in normal conditions.
The group of Farokhzad utilized a thioketal as the ROS-responsive prodrug linkage to develop
nanoparticles for the delivery of the anticancer drug mitoxantrone (MTO).[37] The drug was
transformed into a polyprodrug through the use of an ROS-cleavable thioketal-containing
linker, and self-assembled with lipid-polyethylene glycol to form polyprodrug nanoparticles
(polyMTO NP). Upon exposure to a high concentration of ROS, the nanoparticles could
undergo an ROS-responsive elimination reaction, inducing chain-breakage release of intact
drug molecules leading to significant inhibition of tumor cell growth both in vitro and in vivo.
In comparison, the nanoparticles remained nontoxic in non-oxidative conditions.
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Figure 3. Schematic illustration of the poly mitoxantrone (MTO)-based nanoparticle platform for targeted and deeply
penetrating cancer therapy. a, b) After intravenous injection, the internalising RGD (iRGD)-mediated targeting
strategy facilitates the tumor tissue penetration and tumor cell uptake of the nanoparticles. c) Subsequently, the high
level of ROS in cancer cells can break thioketal bond in the polyMTO to induce chain-breakage patterned release of
intact MTO for d) disrupting DNA synthesis and efficient cancer therapy. DSPE-PEG-[(1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)], mitoxantrone (MTO). Reprinted with permission from ref 37.
Copyright 2017 Wiley.
A thioether-based ROS-responsive prodrug system was investigated by Liu et al.[38] They
designed hyperbranched polymer micelle prodrugs of the anticancer drug SN38, utilizing a
thioether linkage for conjugation of the drug to the polymer backbone. In the presence of H2O2,
the thioether linkage could be oxidized into sulfones or sulfoxides, resulting in hydrolysis and
subsequent release of the SN38. Additionally, the micelles encapsulated cinnamaldehyde (CA),
which could induce further intracellular ROS production, thereby accelerating the release of the
anticancer drug. The prodrug system with encapsulated CA demonstrated increased
cytotoxicity when compared to the free drug, and was selective for an ROS environment.
Redox-responsive systems
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Overexpression of the cell protectant glutathione (GSH) occurs in some tumor tissues, and the
resultant increased concentration of this compound has been exploited by nanoparticles
endowed with GSH sensitive functionalities for intracellular drug delivery. In general, GSH is
responsible for regulating the cellular reductive microenvironment, and is found at
approximately 100-1000 times higher levels in intracellular compartments than in human
plasma and blood. In addition, some tumor cells express cytosolic GSH to levels above 4 times
higher (2-10mM) than normal cells, allowing for cancer-specific intracellular therapeutic
delivery after cellular uptake.[39] Some select examples are discussed below, with a more
comprehensive overview to be found in other recent reviews.[40]
Suna et al.[41] recently demonstrated that a prodrug polymer with a redox responsive disulfide
bridge had higher drug release and consequent antitumor activity when compared to its redox
insensitive polymer counterpart, both in vitro and in vivo. Through reversible addition
fragmentation chain transfer (RAFT) polymerization, they synthesized two prodrug block
copolymers using hydrophilic poly(oligo(ethylene glycol) methacrylate (POEG) with
hydrophobic N-methacryloyl-N-(tert-butoxycarbonyl)aminohexyl methacrylamide (MBA,
redox-insensitive) or N-methacryloyl-N’-(tert-butoxycarbonyl)cystamine (MBC, redox-
sensitive). Dasatinib (Das-an oncogenic tyrosine kinase inhibitor) was then attached covalently
to the hydrophobic block of the block copolymers to attain the final redox responsive or non-
responsive prodrug polymers (POEG-b-PSSDas and POEG-b-PCCDas respectively). These
polymers were then additionally loaded with Doxorubicin to form self-assembling micellar
structures with doxorubicin (DOX) in the core and Dasatinib attached to the polymer chains
forming a dual drug delivery system. Owing to the high GSH concentration in tumor cells, the
DOX loaded POEG-b-PSSDas showed triggered release of both drugs with an enhanced
antitumor effect and prolonged survival rate in an aggressive murine breast cancer model
(4T1.2) when compared to DOX or DOX+Das loaded POEG-b-PCCDas micelles.
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In an interesting example by Tappertzhofen et al.,[42] cationic block copolymers containing
disulfide bonds were used to form polyplexes with negatively charged pDNA for gene delivery.
A family of cationic block polymers, in this case polylysine-b-p[HPMA] with different ratios
of HPMA and lysine, were synthesized using RAFT polymerization, as well as a similar set of
polymers with a disulfide bridge between the two blocks, i.e. polylysine-S-S-b-p[HPMA] to
endow the carriers with bioreductive responsiveness. Two selected cationic polymers, with and
without a disulfide bridge, and with HPMA: Lysine ratio 7:1, were used to form polyplexes
with pDNA by physical mixing to give polyplex micelles. Both polymer complexes showed
successful internalization by HEK-293T cells, however the transfection abilities of the
polymers differed greatly. As a negative control, pDNA alone showed no detectable
transfection, as well as a very low transfection efficiency for the polyplex without the disulfide
bridge. On the other hand, the pDNA-polymer complex with the disulfide linker mediated a
high transfection frequency of the EGFP+ cells in a dose dependent manner without inducing
toxicity. Similarly, Tai et al.[43] designed and synthesized arginine, histidine and stearyl
containing polypeptides crosslinked via disulfide linkers (SHRss) to act as bioreducible carriers
of siRNA. Arginine was chosen for its ionic interactions with the negatively charged RNA,
histidine for its ability to act as a proton sponge and raise the pH in the endosome for endosomal
escape of the polymer-RNA complex and stearyl moieties for enhanced cellular uptake and
endosomal escape. The zeta potential and particle size of SHRss/siRNA complexes were found
to be dependent on the N/P ratio, with optimal values for cellular uptake (>200nm, 25mV) noted
for N/P values >5. Cellular uptake of the SHRss/siRNA complexes into Luc-HeLa cells was
found to be higher than the nonreducible controls, and in Luc-HeLa and mCherry-HEK293
cells, SHRss groups showed higher gene silencing than nonreducible SHR groups at all N/P
ratios, which was attributed to the combined effect of the presence of the stearyl and disulfide
moieties. Subcellular trafficking and localization of the siRNA in the cytoplasm was
demonstrated, with SHRss2/Cy3-siRNA transfected cells showing enhanced endosomal escape
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and uniform distribution in the cytoplasm when compared to LF2000-positive vector and
nonreducible SHR/siRNA complex controls. In vivo studies showed that the accumulation of
SHRss2/Cy5-siRNA complexes within Luc-HeLa xenograft tumors was ~ 6-fold higher than
that of Cy5-siRNA treatment, in which the gene silencing effect of redox-responsive
SHRss2/siLuc complexes measured by luciferase gene silencing showed weakened tumor
luminescence post treatment, while SHRss2/NC-siRNA treatment showed no change.
As well as achieving disulfide bridge reduction, redox conditions can also act as a trigger for
other kinds of responsive functional groups or linkers. To this end, Shen et al.[44] recently
designed a strategy for combined release of Paclitaxel and Cisplatin from an injectable
thermoresponsive hydrogel system. The hydrophobic ends of two diblock mPEG-PLGA
(Polyethylene glycol - PEG, Poly(lactic-co-glycolic acid) - PLGA) polymers were covalently
linked to a Pt(IV) prodrug, which could be converted to the active cisplatin drug in the reductive
intracellular environment. PTX was also encapsulated in the hydrophobic core of the self-
assembled core-shell structure of the amphiphilic polymers. Due to the thermoresponsive
behaviour, at temperatures greater than 37°C, the system underwent a sol-gel transition, as well
as demonstrating efficient tumor inhibition efficacy and sustained release for up to 2.5 months
owing to the bioreducible nature of the carrier. A similar approach was described by Xiao et
al.[45] in which a Cisplatin(IV) prodrug and Rhodamine B were attached independently to
mPEG-b-PCL-b-PLL (PEG-polyethylene glycol, PCL-polycaprolactone, PLL-poly-L-lysine)
backbone, and the mixed prodrug micelles could achieve efficient drug release and antitumor
efficiency due to the low pH and reductive intracellular environment.
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Figure 4. Design of hydrogel formulation for the combination delivery of cisplatin and PTX. (a) Molecular structures
of the mPEG-PLGA diblock copolymer, Pt(IV) prodrug, and PTX. (b) Cartoon representation of mPEG-PLGA–Pt(IV)
polymer prodrug conjugate and its self-assembly with PTX. (c) Thermo-responsive sol-gel transition by the polymer-
prodrug conjugate loaded with PTX and redox sensitive co-delivery of PTX and cisplatin by the drug carrier gel.
Reprinted with permission from ref 44. Copyright 2017 American Chemical Society.
Finally, it is worth mentioning an example of a bioreducible carrier featuring diselenium bonds
to achieve redox-responsive drug delivery. The Se-Se bond has a lower bond disassociation
energy (172 kJ/mol) compared to that of the S-S link (240kJ/mol), and thus if properly shielded
against nonspecific release in non-reductive conditions, the diselenide linker has the potential
for more efficient and rapid drug delivery in cancer cells.[46] In this context, Wei et al.[47]
recently demonstrated that a diselenide appended poly(ester urethane) triblock copolymer
(PAUR-SeSe) was able to release more drug when compared to the S-S containing poly(ester
urethane) triblock copolymer (PAUR-S-S). Under similar GSH concentrations (30 mM),
PAUR-SeSe micelles released 85 % of the encapsulated DOX, whereas 67 % of the drug was
released by PAUR-S-S micelles in 48 hours. In subsequent in vitro experiments, HN30 cells
were treated with free DOX (negative control), PAUR-S-S-DOX (positive control) and PAUR-
SeSe-DOX, and both micelles showed enhanced anticancer efficiency when compared to free
DOX. Furthermore, DOX loaded PAUR-SeSe demonstrated six-fold higher antitumor effect
than the S-S analogue, due to the faster cleavage and enhanced drug release of the diselenium
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bond in the reductive intracellular environment. While this example is most correctly described
as a system in which the drug is encapsulated rather than covalently bound as a pro-drug, it
nevertheless has strong analogies to polymer pro-drug strategies in that the overall
macromolecular carrier uses diselenium bonds in a stimulus-responsive manner, but more
extensive in vivo characterization will be needed before these chemistries can be considered for
possible clinical use.
Stimuli responsive self-immolative materials
An emerging area of materials research involves the use of endogenous and /or exogenous
stimuli to catalyze the controlled deconstruction of macromolecular structures and in so doing,
to accelerate drug release.[48] These so-called ‘self-immolative’ materials, usually designed
around dendrimer, oligomer and linear polymer structures, are encoded to respond to external
stimuli through the cleavage of a trigger, which leads to a cascade of intramolecular chemical
reactions resulting finally in the complete degradation of the polymer into small molecules
which are easily cleared. In this section we report some of the most recent proof-of-concept
studies highlighting the potential of self-immolative materials for drug delivery and other
biomedical applications. For further discussions of the concepts underlying self-immolative
materials, including aspects such as strategies for their synthesis, architectures, chemical nature
of the linkers and deconstruction profiles, we refer the reader to more specialist reviews.[14g, 14i,
48-49]
Azobenzene derivatives have been intensely exploited in the context of stimuli-responsive
materials for their reversible trans-cis photo-isomerization that occurs upon exposure to UV-
vis light. However, it been demonstrated only recently[50] that in addition to the tendency to
photo-isomerize, azobenzene derivatives can also undergo chemical reduction with subsequent
1,6-elimination, triggering the de-polymerization of a self-immolative polymer.[51] Eom et al.[52]
designed a graft copolymer bearing an azobenzene motif for the redox-activated delivery of
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DOX in the colon. In this way, they could also exploit the fact that azobenzene moieties can be
cleaved by azo-reductase enzymes present in the intestinal microbial flora. The copolymer was
prepared through atom transfer radical polymerization, and was initially of neutral charge,
however, upon redox-azobenzene-cleavage, a cascade of events released a free ammonium
cation on the polymeric side chains. Once activated, the positively charged DOX-polymer
conjugate could be taken up by HT-29 cells, and showed comparable cytotoxicity to the free
drug, while the neutral non-activated copolymer did not show any appreciable toxicity. It is
important to note that the azo-bond can be also reduced/cleaved under hypoxia conditions,
which further opens up new avenues for the development of drug delivery systems.
Xie et al.[53] developed a simple and elegant self-immolative polymeric nanoparticle system to
act as a dual-function vector for delivery of therapeutic miRNA and targeting of dysregulated
polyamine metabolism in cancer. The nanoparticles were based on a biodegradable polycation
prodrug, and included GSH-reducible disulfide bridges within the backbone of the disulfide-
bis(ethylnorspermine) (DSS-BEN) polymer, which were able to induce selective triggering of
nanoparticle degradation within the cytoplasm of cells. The nanoparticles were able to
demonstrate effective miRNA release and depletion of natural cellular polyamine levels.
Finally, the concomitant miR-34a expression and polyamine metabolism regulation
demonstrated enhanced cell killing in vitro in HCT116 human cancer cells, as well as superior
antitumor activity in an in vivo tumor model.
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Figure 5. Mechanism of action of disulfide-bis(ethylnorspermine) (DSS-BEN)/miR-34a nanoparticles. (A) DSS-
BEN condenses miRNA into nanoparticles by electrostatic interactions. (only linear form of DSS-BEN is shown but
branched forms are also present) (B) Upon endocytosis and endosomal escape, the particles are subjected to
cytoplasmic reduction by GSH, followed by disassembly and release of both BENSpm and miR-34a mimic.
BENSpm induces expression of enzymes involved in polyamine catabolism, which reduces intracellular
polyamine levels. MiR-34a mimic increases cellular miR-34a levels, which leads to Bcl-2 downregulation.
Reprinted with permission from ref 53. Copyright 2017 Elsevier.
A novel biodegradable polyurethane bearing a pendant redox-trigger (p-nitrobenzyl alcohol/ p-
NBA), a 1,5-cyclisation spacer (N-2-(hydroxyethyl)ethylene diamine) and a self-immolative
linker (p-hydroxylbenzyl alcohol) was prepared by C.-H. Whang and collaborators.[54] The
incorporation of p-NBA in the polyurethane backbone allows for potential enzymatic reduction,
such as by nitroreductases expressed in pathological bacteria, as well as demonstrating an
alternative functionality for redox degradation rather than the typical disulfide bridges. Self-
immolative polymer degradation through alternating 1,6-elimination decarboxylation and 1,5-
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intramolecular cyclisation was assessed, as well as reductive triggered release of paclitaxel from
the nanoparticles. The redox-triggered polymer disassembly enabled paclitaxel release three
times faster than that of the untreated nanoparticles.
The stimuli-responsive self-immolative polymer concept has been used to develop sacrificial
layer materials for the controlled release of actives in the presence of triggering conditions.[55]
Ergene et al.[56] reported the first example of a self-immolative polycation exerting a fast and
broad-spectrum antimicrobial activity. The polycation comprised cysteamine-functionalized
poly (benzyl ethers) with silyl end-capping, and retained antibacterial activity upon
depolymerization after fluorine specific treatment. The unzipping of the polymeric backbone
released molecules with higher solubility and lower hemolytic toxicity compared to the original
polymer. Han et al.[57] described the first example of self-immolative electrospun nanofiber
membranes based on a self-immolative polymer and polyacrylonitrile, which showed
depolymerization 25 times faster than that of a cast film of the same blend. This led to a drastic
change in surface properties from highly hydrophobic (110°) to hydrophilic (0°). The same
blend was also coaxially electrospun in the presence of polyvinylpyrrolidone/dye as a loaded
core, in order to assess the triggered release of the model dye. The nanofibers showed almost
no release of the encapsulated material in non-triggering conditions, while immediate dye
release was observed in triggering solutions. This approach can be considered as a proof-of-
concept for the customisation of on-demand release of components embedded into fibers.
Combination therapies
In order to enhance the performance of stimuli-responsive prodrugs, it has increasingly become
common to design systems that respond to more than one stimuli, resulting in an enhancement
of efficacy or a construct that responds over a range of varying conditions. While drug delivery
through exogenous stimuli was not covered in the present review, the examples discussed below
introduce the potential for combination approaches utilizing either two endogenous stimuli, or
a combination of endogenous and exogenous stimuli to improve treatment efficacy.
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In one example, Liu et al.[58] prepared a multifunctional prodrug comprising gemcitabine
conjugated to a photosensitizer, meso-tetraphenylporphyrin (TPP) through a reactive oxygen
species cleavable thioketal linker. Upon irradiation by red light, the TPP generated singlet
oxygen species, which not only caused cell damage directly but also which was able to cleave
the ROS-responsive thioketal linkage of the prodrug, resulting in gemcitabine release and
further enhanced cell damage. This approach thus demonstrated the feasibility of a
multifunctional prodrug with on-demand remote spatiotemporal control of drug release. While
increased levels of intracellular ROS are typical for cancer cells, this external approach reduces
the chance of biological variability, and generates a more effective concentration of ROS. A
similar approach was demonstrated by Zhou et al.,[59] who developed a ROS-responsive prodrug
vesicles for on-demand delivery of doxorubicin in Triple Negative Breast Cancer. Their
vesicles were assembled from an ROS-activatable Dox prodrug, a poly(ethylene glycol) (PEG)-
modified photosensitizer pyropheophorbide-a (PPa), an unsaturated phospholipid and
cholesterol. Upon laser irradiation, ROS were generated within the vesicles, thereby activating
the DOX prodrug through cleavage of a thioketal spacer, resulting in delivery at the tumor site
for combined local-regional chemotherapy and PDT. Additionally, the produced ROS could
oxidize the unsaturated lipids, causing an increase in the permeability of the lipid membrane,
triggering ultrafast release of the drug.
Bio et al.[60] implemented a combined PDT/chemotherapy approach for the delivery of an
aminoacrylate prodrug of combretastatin A-4 (CA4) to tumor cells. Far-red light, such as that
utilized during PDT, was used activate the photosensitizer phthalocyanine to produce a high
local concentration of singlet oxygen species, which subsequently cleaved the aminoacrylate
prodrug linker to locally release CA4.[61] The released CA4 resulted in toxic effects on cancer
cells both in vitro and in vivo in tumor models, in comparison to a non-degradable prodrug
control that showed no drug release or toxicity in vivo.
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In an example of a combination approach using two endogenous stimuli, Gu and co-workers
developed a nanocarrier carrying a prodrug of the anticancer drug SN38 that was responsive to
both a reducing and oxidative environment.[62] The rationale for this work was the inherent
heterogeneity characteristic of many tumor types, resulting in potential areas of enhanced
intracellular glutathione (GSH) co-existing with regions of overproduced ROS, either through
different tumors, different regions within a tumor, or even one tumor cell at different stages.[63]
Based on this, they designed their nanocarrier to contain a prodrug of the phenol ester of SN38
conjugated to an oligomeric ethylene glycol carrier through a thioether-ester moiety. In a
hydrophobic environment, the phenol ester was designed to remain stable, however in a
hydrophilic environment, the phenol ester was intended to cleave rapidly, initiated through
ROS-mediated oxidation of the thioether to a hydrophilic sulfone or sulfoxide. Gu et al
observed that the phenol ester could undergo glutathione-triggered thiolysis, and therefore their
system was able to decompose and quickly release the drug when triggered by either GSH or
ROS, or the two in combination. Their nanocarrier successfully released SN38 in in vitro
assays, and further showed efficacy in in vivo tumor model, where mice implanted with
xenograft breast tumors showed significantly higher SN38 concentration in tumor tissues
compared to control. Further in vivo experiments in a colorectal model showed significantly
improved survival rates and tumor growth inhibition for the mice receiving the degradable
prodrug treatment compared to free drug.
Zhang et al.[64] synthesized a novel drug-delivery enzyme and redox dual-responsive polymeric
nanocarrier platform with active targeting abilities, in order to achieve rapid intracellular cargo
release for cancer treatment (see Figure 6). The dual-responsive targeting polymeric micelles
were produced through the self-assembly of a mixture of two polymeric materials. The first
material was a polymeric-prodrug of camptothecin, synthesized through conjugation of the drug
(Camptothecin-CPT) to monomethyl poly (ethylene glycol) (PEG) via a redox-responsive
linker (s-s) (mPEG-ss-CPT). The second material was an amphiphilic block copolymer
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synthesised through the conjugation of a hydrophobic polycaprolactone (PCL) block to a
hydrophilic PEG via an azobenzene spacer (Azo) for enzyme-responsiveness. The PEG chains
were further decorated with phenylboronic acid (PBA) to provide the final micelles with active
targeting features (PBA-PEG-Azo-PCL). In vitro assays in simulated tumor cell
microenvironment conditions confirmed that the micelles could be disrupted in the presence of
azoreductase, resulting in rapid release of camptothecin. In vivo experiments confirmed that the
micelles had enhanced speciﬁcity towards subcutaneous hepatoma carcinoma cells through the 
active targeting, and demonstrated remarkable therapeutic activity to liver H22 tumors with low
toxicity to normal tissues, resulting in a survival rate of approximately 100 % after 160 days of
treatment.
Figure 6. Schematic design of enzyme and redox dual-triggered intracellular release from actively targeted polymeric
micelles to enhance cancer treatment. Abbreviations: monomethyl poly (ethylene glycol) (PEG), redox-responsive linker
(s-s), camptothecins (CPT), polycaprolactone (PCL), azobenzene spacer (Azo) phenylboronic acid (PBA). Reprinted
with permission from ref 64. Copyright 2017 American Chemical Society.
A facile approach for preparing multi-stimuli responsive branched DOX-conjugate-copolymers
with high molecular weight (around 165 kDa) was recently reported by Wei et al.[65] The
branched DOX-conjugated materials were based on poly N-(2-
hydroxylpropyl)methacrylamide), obtained through a one-pot RAFT copolymerization with
enzyme-sensitive (papain or cathepsin B) cross-linkers. DOX was coupled to the branched
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polymer backbone post-polymerization through pH-sensitive hydrazone bonds, and release of
DOX in a pH-dependent manner was observed over a reasonable timeframe from the pre-
formed nanoparticles. The self-assembled nanoparticles showed rapid stimuli-responsive
breakdown, releasing fragments with low molecular weights that could be easily cleared by the
body. The particles were approximately 100 nm in size, with a negative surface charge to ensure
good in vivo stability. Finally, the nanoparticles were observed to accumulate in tumor tissue
to a higher degree than the free drug control, leading to an enhanced anti-tumor effect against
4T1 tumor models, with no adverse side effects observed in vivo.
Li et al.[66] demonstrated enhanced delivery of PTX to tumor cells using enzyme and redox
dual-responsive carriers, by conjugating PTX to hydroxyethyl starch (HES) using a disulfide
linker (HES-SS-PTX). The HES-SS-PTX conjugate self-assembled in water to form redox
responsive nanoparticles with a diameter of 150nm with ~ 6 % PTX loading. The α-1,4 
glycosidic bond of HES was cleavable by α-amylase, endowing the NPs with dual 
responsiveness. The resulting particles showed an increased half-life and higher accumulation
in the tumor site when compared to a commercially available PTX formulation. In a reductive
cancer cell environment, cleavage of the disulfide bonds triggered collapse of the nanoparticles
and burst release of the drug, while in parallel the HES shell degradation by α-amylase enzymes 
allowed deeper penetration of the particles into the tumor site. Finally, HES-SS-PTX
demonstrated improved in vivo anti-tumor efficacy (64 %) and lower cytotoxicity when
compared to Taxol (52 %) in 4T1 tumor- bearing mice.
Mavuso et al.[67] recently described a redox and pH dual-responsive copper-ligand
nanoliposome bioactive complex for the treatment of chronic inflammation. Pathological sites
are prone to an oxidative imbalance due to formation of ROS and other metabolites, which
triggers a counteractive upregulation of antioxidants such as GSH, and thus the authors targeted
the presence of upregulated GSH, as well as the low pH in inflamed tissues to achieve drug
delivery. For this purpose, Cu(II) was used to link predinosolone succinate (PS) in the presence
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of a glyglycine (glygly) ligand to yield a copper ligand bioactive complex [Cu(glygly)(PS)].
This bioactive complex was then loaded into a cystamine-appended cationic Eudragit E100
polymer (EuE100-Cyst) with a phospholipid bilayer to give pH and redox responsive nanolipids
(NLs). The [Cu(glygly)(PS)] complex demonstrated improved inflammatory and oxidant
inhibitory activity when compared to free PS drug, and the free radical scavenging activity
(60 %) and lipoxygenase (LOX-5) inhibitory effect (37 % ) of the complex was also found to
be higher than for the free drug (4 % and 6 % respectively). The low pH also had significant
impact on the drug release, with > 75 % released at pH 5 in 6 hours, while only 23 % release
was recorded at pH 7.4. These results suggest the potential of such pH and redox responsive
systems for the treatment of inflammatory conditions.
Self-immolative polymersomes have been produced from the self-assembly in water of
copolymers with a hydrophilic block based on poly (N,N-dimethylacrylamide), and a self-
immolative hydrophobic polycarbonate block caged with perylen-3-yl, 2-nitrobenzyl or
disulfide moieties.[68] Upon removal of the caging moiety triggered by either UV-vis light or
reductive stimulus, the block copolymer degraded into water-soluble small molecules.
Triggered drug co-release and controllable access toward proton, oxygen, and enzymatic
substrates could be achieved for the guest-loaded self-immolative-polymersomes. Logic gate
combined applications of triggers (OR, AND and XOR-type) in programmed enzymatic
catalysis were also demonstrated.
The Gillies group designed a library of UV, H2O2 and thiol multi-responsive end-cap linkers,
which were subsequently used to prepare a set of amphiphilic poly(ethyl glyoxylate)-poly
(ethylene oxide) copolymers.[69] These materials were able to self-assemble into nanoparticles
with sizes of less than 100 nm, and their depolymerization could be triggered at concentrations
of DTT and H2O2 less than 0.01 equivalents relative to monomer, confirming an amplified
cleavage of the multi-responsive end-cap linkers leading to disruption of the nanoparticles.
Finally, doxorubicin, coumarin and Nile Red specific release were modulated by selectively
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tuning the external stimulus. The facile variability of the polymer-drug linkers makes these
materials appealing as multi-responsive platforms, suggesting further possibilities as their uses
as drug-delivery carriers.
Conclusions
This review has aimed to cover some of the leading examples of pro-drug chemistries used to
endow polymers with controlled and site-specific drug delivery properties. The heterogeneous
nature of pathogenic sites with respect to normal cell environments, and with with inherent
associated conditions such high reduction potential, hypoxia, low pH, overexpressed enzymes
and high ROS, has been the primary inspiration for the design of prodrug systems responsive
to these specific changes acting as stimuli. Accordingly, the chemistries that have been shown
to be effective for controlled delivery of therapeutics in response to these particular disease
environments should be capable of translation across different types of disease. For example,
in the treatment of infectious diseases, there are many problems in common with cancer
therapies such as systemic exposure of cytotoxic agents, sub-therapeutic dosing in cases of
narrow therapeutic window agents and the development of resistance. Polymer therapeutics
with site-specific release induced by local biological cues or orthogonal stimuli can therefore
be readily used in acute and chronic infections, and some promising examples have recently
emerged.[70] Oxidative stress is also an important component of certain cardiovascular
disorders, and nanoparticles which are responsive to ROS have shown efficacy in myocardial
ischaemia models.[71] It is also worth noting that combination systems, both in terms of
combinations of stimuli, and involving combinations of active molecules, show potential in
multiple therapeutic areas. Regenerative medicine, in which diverse cell populations require
different cytokines and growth factors at different times and in defined spatial regions during
growth, is perhaps one of the most exciting areas for responsive polymer pro-drugs. It is our
perspective that the advances made in the specific release of drugs as shown in this article will
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strongly apply to delivery strategies in fields other than oncology, and we hope that this view
encourages researchers into new, and as yet unexplored, clinical challenges.
However, for any clinical applications of polymer pro-drug materials there remain numerous
scientific and practical barriers which must be overcome. Safety and efficacy are the most
important criteria for any therapeutic and the complexities of polymer therapeutics make the
establishment of full safety profiles time-consuming and expensive. For regulatory approval,
pro-drugs of any type must be evaluated for all breakdown products, and the pharmacokinetic
and pharmacodynamics properties of most synthetic polymers are highly complicated even
without consideration of the multiple fragments which can be produced on biodegradation. For
orally dosed formulations, the requirements are less severe, as excretion of large molar mass
fragments is more rapid, but nevertheless, the quantitative release of drugs from polymer pro-
drug carriers still needs to be established, and with multiple drug-linker-carrier breakdown
products this adds significant difficulty to a full safety and efficacy study. Potential re-uptake
of low molar mass species may occur following oral therapy, and effects on gut microflora may
also be significant for the patient’s health. The issues for injectable polymer formulations are
even more formidable, owing to the requirements for absolute sterility over prolonged storage
and administration, multiple organ exposure once injected, and uncertainties in circulatory
dynamics for different molar mass fragments and breakdown products. The common
assumption that all the low molar mass breakdown products will be rapidly cleared is also
questionable for injectable formulations as multiple re-uptake and processing pathways may
exist for fatty acid type fragments emerging from polymer degradation. Nevertheless, there is
now a considerable clinical database for injected nanomedicines over > 20 years, and a host of
powerful new pre-clinical models to evaluate investigational therapeutics. New imaging
modalities are enabling the detection of nanomaterials, fragments and biomarkers at ever-
increasing sensitivity, and longitudinal studies as well as large-scale genomic data are providing
patient information for many more indications beyond oncology
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Accordingly, if research into the advanced therapeutics outlined in this article continues to
advance, and if the regulatory and complexity issues can be solved at affordable cost, then there
are many possibilities for polymer pro-drugs to address successfully some of the most pressing
current medical needs.
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